This highlights that changes in the expression of TGF-β molecules of CTCs could serve as novel biomarkers for the early prediction of therapeutic response in patients with unresectable HCC undergoing Atezo+Bev. This evidence concerns the gene TGFB1 and hepatocellular carcinoma.